Chungnam National University Hospital
Daejeon, 301-040, South Korea
NCT Number: NCT00630214
the increased risk of hypocalcemia following total thyroidectomy plus central neck dissection can be minimized by routine administration of oral calcium and vitamin D supplements during the early postoperative period.
Looking for future studies?
Notify Me15 year–85 year
All sexes
Interventional
Phase 2
Daejeon, 301-040, South Korea
Of patients with differentiated papillary thyroid carcinoma, group D underwent total thyroidectomy alone and groups A-C underwent total thyroidectomy plus CND. The latter were randomized to oral calcium (3 g/day) plus vitamin D (1 mcg/day) (group A, n = 49), calcium alone (group B, n = 49), or no supplements (group C, n = 50). Hypocalcemic symptoms, serum calcium, and parathyroid hormone (PTH) levels were compared among the groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
Other names: calcium carbonate and one-alpha (vitamin D)
calcium carbonate (3 g/day, 1 g every 8 h)
Other names: calcium carbonate (Korea United Pharmaceutical Co, Seoul, Korea)
Time frame: To postoperative 12 months
Asan Medical Center
Other
Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00743782
Autoimmune Diseases, Autoimmune Polyendocrine Syndrome Type 1
Bethesda, Maryland, United States
View Trial DetailsNCT06716632
Calcium Metabolism Disorders, Hypocalcemia
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05216419
Avitaminosis, Calcium Metabolism Disorders
Seoul, South Korea
View Trial DetailsNCT05260255
Autoimmune Diseases, Avitaminosis
Bangkok, Thailand
View Trial Details